Livsat Tablet contains Ursodeoxycholic Acid 300mg, a hydrophilic bile acid used primarily in the treatment of various hepatobiliary disorders. Ursodeoxycholic Acid acts by reducing the cholesterol content of bile, thereby decreasing cholesterol saturation and promoting the dissolution of cholesterol gallstones. It also exhibits cytoprotective properties by stabilizing hepatocyte membranes and improving bile flow, which aids in the management of cholestatic liver diseases such as primary biliary cholangitis and intrahepatic cholestasis. Livsat is indicated for patients with non-calcified cholesterol gallstones who are not candidates for surgery and for those with chronic liver conditions characterized by impaired bile secretion. The medication is generally well-tolerated, though some patients may experience mild gastrointestinal disturbances including diarrhea, nausea, or abdominal discomfort. Caution is advised in patients with biliary obstruction or acute inflammation of the gallbladder. Regular monitoring of liver function tests is recommended during therapy to assess treatment response and detect potential adverse effects. Livsat Tablet should be administered under medical supervision, with dosage tailored to individual patient needs based on clinical evaluation. It is contraindicated in patients with known hypersensitivity to Ursodeoxycholic Acid or its components.